Publications by authors named "E Windt"
Background: mRNA-1283 is an investigational COVID-19 mRNA vaccine encoding the receptor-binding and N-terminal domains of the SARS-CoV-2 spike protein in contrast to the original mRNA-1273, which encodes the full-length spike protein.
Methods: A phase 2a, dose-ranging, observer-blind, randomized study (NCT05137236) conducted in adults (≥18 years) previously vaccinated with mRNA-1273 evaluated the safety and immunogenicity of a single dose of mRNA-1283 (2.5, 5, and 10 µg) and its bivalent formulation, mRNA-1283.
Introduction: Vaccination against SARS-CoV-2 is an integral pillar of the public health approach to COVID-19. With the emergence of variants of concern that increase transmissibility and escape from vaccine- or infection-induced protection, vaccines have been developed to more closely match the newly circulating SARS-CoV-2 strains to improve protection. The safety and immunogenicity of multiple authorized messenger RNA (mRNA)-based COVID-19 vaccines targeting the omicron sublineage (BA.
View Article and Find Full Text PDFBackground: Solid organ transplant recipients (SOTRs) are at high risk for severe COVID-19.
Methods: This open-label, phase 3b trial evaluated mRNA-1273 in 137 kidney and 77 liver SOTRs and 20 immunocompetent participants. In part A, SOTRs received three 100-µg doses of mRNA-1273; immunocompetent participants received 2 doses.
Article Synopsis
- The study investigated the safety and effectiveness of omicron BA.1 monovalent and bivalent booster vaccines compared to the original mRNA-1273 vaccine in a large, randomized trial involving participants aged 16 and older.
- Conducted in the UK, the trial assessed antibody responses and safety profiles, focusing on the immune response at day 29 after administration of the boosters.
- A total of 3,098 participants were enrolled, with results showing differing immune responses between the new omicron boosters and the original vaccine, aiming for both non-inferiority and potential superiority.
Introduction: Several drugs have been associated with druginduced sarcoidosis-like reactions (DISRs) that are clinically indistinguishable from sarcoidosis. Daclizumab is a humanized monoclonal IgG1 antibody that binds to CD25 that has been studied for the treatment of multiple sclerosis (MS). During MS clinical trials of daclizumab, 12 subjects developed clinical conditions potentially consistent with sarcoidosis.
View Article and Find Full Text PDF